[Meta-analysis of efficacy and safety on neoadjuvant therapy for rectal cancer].
Zhonghua Wei Chang Wai Ke Za Zhi
; 15(11): 1150-5, 2012 Nov.
Article
em Zh
| MEDLINE
| ID: mdl-23172528
ABSTRACT
OBJECTIVE:
To assess the value of neoadjuvant therapy for resectable rectal cancer and the impact on postoperative complications.METHODS:
Literature search was performed in PubMed, Ovid, Web of Science, Springer-Link and Elsevier ScienceDirect for randomized controlled trials published before May 2010 that compared neoadjuvant therapy with surgery alone or postoperative adjuvant therapy. The computer search was supplemented with hand search of reference lists for available primary studies. Inclusion criteria and quality assessment were performed.RESULTS:
Eleven studies including 7407 patients were enrolled for analysis. Neoadjuvant therapy group had significant advantages in local recurrence (OR=0.43, 95%CI0.37-0.50, P<0.01), distant recurrence (OR=0.85, 95%CI0.76-0.95, P<0.01), 5-year overall survival (RR=1.15, 95%CI1.04-1.28, P<0.01), and sphincter-saving surgery (RR=1.48, 95%CI1.17-1.87, P<0.01). There were no significant difference in postoperative mortality rate(OR=1.20, 95%CI0.68-2.13, P=0.53) and anastomotic complications (OR=1.04, 95%CI0.73-1.48, P=0.84).CONCLUSION:
Neoadjuvant therapy improves local control, distant recurrence and long-term survival without increasing postoperative complications.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Retais
/
Terapia Neoadjuvante
Tipo de estudo:
Clinical_trials
/
Systematic_reviews
Limite:
Humans
Idioma:
Zh
Ano de publicação:
2012
Tipo de documento:
Article